STAT3 and neoplasm: To understand the role of STAT3 in CXCL9-mediated tumour progression, we injected STAT3 inhibitor STATTIC (25 mg/kg, twice per week, intraperitoneally) to CXCL9-treated PAAD mice [30], and we found that compared with CXCL9-treatment only, STATTIC co-injection could significantly reduce the orthotopic tumour growth, and the infiltration of CD8+ cells into PAAD tumour was recovered (Figure 6H–6K).